Resisting the Temptation to Oversimplify Antiplatelet Resistance⁎⁎Editorials published in JACC: Cardiovascular Interventions reflect the views of the authors and do not necessarily represent the views of JACC: Cardiovascular Interventions or the American College of Cardiology.  by Bhatt, Deepak L.
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esisting the Temptation to
versimplify Antiplatelet
esistance*
eepak L. Bhatt, MD, MPH, FACC
oston, Massachusetts
he variable response of platelets to different antiplatelet
edications, often referred to as antiplatelet resistance, has
enerated immense interest among both clinicians and
nvestigators. In several studies, variability in antiplatelet
esponse has been associated with adverse cardiac outcomes.
See pages 649 and 654
n patients undergoing elective percutaneous coronary in-
ervention (PCI) who had not received glycoprotein (GP)
Ib/IIIa inhibitors or clopidogrel pre-treatment, aspirin
onresponsiveness predicted periprocedural myocardial in-
arction (MI) (1,2). Similarly, clopidogrel nonresponsive-
ess has been associated with adverse outcomes, including
eriprocedural myonecrosis, stent thrombosis, MI, and even
eath (3–5). More recently, therapeutic strategies have been
ssigned on the basis of platelet responsiveness and seem to
mprove surrogate markers of clinical outcome (6). Not all
tudies, however, have been consistent in finding the afore-
entioned associations (7,8). Conflicting results have
aused a great degree of confusion in the field about whether
o test, how to test, in whom to test, and what to do with the
nformation obtained from a test.
Editorials published in JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-
ions or the American College of Cardiology.
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go; the compensation was donated to a nonprofit organization).In this issue of JACC: Cardiovascular Interventions, 2
mportant reports examine critical issues surrounding vari-
bility in antiplatelet response. In patients who have re-
eived an intravenous GP IIb/IIIa inhibitor, the study by
aw et al. (9) demonstrates that neither aspirin nor clopi-
ogrel nonresponsiveness affects periprocedural myonecro-
is. The study by Cuisset et al. (10) finds that in patients
ho are clopidogrel nonresponders, those randomized to
eceive a GP IIb/IIIa inhibitor had a significantly lower rate
f cardiovascular events, consisting primarily of periproce-
ural MI as defined by troponin elevation.
The results of these 2 well-done studies might seem
ontradictory at first glance, but closer examination shows
hat this is not the case. One study seems to find no
rognostic value in point-of-care measurement of aspirin or
lopidogrel response, whereas the other seems to find
mmense value in measuring clopidogrel response, along
ith therapeutic implications. It is important to realize that
oth studies essentially examined the short-term surrogate
utcome of periprocedural myonecrosis. In the presence of
he intravenous GP IIb/IIIa inhibitor eptifibatide, Saw et al.
9) did not find that aspirin or clopidogrel nonresponsive-
ess influenced myonecrosis in a low- to moderate-risk
opulation. Perhaps, had active thrombus been present, the
ndings might have been quite different. It is also possible,
f the study had followed a larger number of patients for a
onger duration of follow-up, that a deleterious effect of
spirin and clopidogrel resistance might have been evident
n end points such as spontaneous MI and stent thrombo-
is.
The study by Cuisset et al. (10) showed that the GP
Ib/IIIa inhibitor abciximab decreased periprocedural MI in
lopidogrel nonresponders as assessed by light transmittance
ggregometry—these were patients who essentially still had
ctivated platelets prone to aggregate. A reduction in
roponin-defined post-procedural myonecrosis is probably a
easonable surrogate of more clinically important outcomes
11). Although the overall sample size was not large, it was
ncouraging that this strategy was not associated with any
xcess in major bleeding, although it might have been
nstructive to examine more minor degrees of bleeding as well.
An interesting finding in the Saw et al. (9) study is that
ow clopidogrel response was significantly associated with
levated body mass index. Other studies have also shown a
imilar relationship between weight and clopidogrel effect
12). Whereas the impaired platelet response seen in obese
atients in this study did not seem to translate into adverse
linical outcomes, future studies will need to explore in
reater depth the relationship between obesity and apparent
ntiplatelet resistance.
Novel agents in development might be particularly useful
n patients with antiplatelet hyporesponsiveness (13). The
ore potent oral thienopyridine prasugrel was recently
valuated in acute coronary syndrome patients undergoing
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661CI in TRITON–TIMI-38 (Trial to Assess Improvement
n Therapeutic Outcomes by Optimizing Platelet Inhibition
ith Prasugrel–Thrombolysis In Myocardial Infarction-38)
nd found to be superior to clopidogrel although with a
ignificant accompanying risk of major bleeding (14–16).
iabetic patients are a group very likely to benefit from
ntensification of their antiplatelet regimen. This phenom-
non of heightened treatment effect in diabetic patients has
een observed with prasugrel versus clopidogrel, with high-
ose versus low-dose clopidogrel, with clopidogrel versus
spirin, and with GP IIb/IIIa inhibitors versus placebo
17–20). Therefore, diabetic patients might benefit from
ore complete platelet blockade, regardless of what tests of
latelet reactivity show.
The CURRENT–OASIS-7 (Clopidogrel Optimal
oading Dose Usage to Reduce Recurrent Events–Optimal
ntiplatelet Strategy for Interventions-7) trial is randomiz-
ng acute coronary syndrome patients to standard or high-
ose clopidogrel, irrespective of clopidogrel responsiveness
21). Cangrelor is a potent intravenous adenosine diphos-
hate receptor antagonist that is being evaluated in the
ngoing CHAMPION (Cangrelor versus Standard Ther-
py to Achieve Optimal Management of Platelet Inhibi-
ion) trials (22,23). If more potent platelet inhibition with
angrelor proves superior to clopidogrel across the range of
atients studied, the issue of measuring clopidogrel respon-
iveness might be moot, at least with respect to modifying
eriprocedural outcomes. The GRAVITAS (Gauging Re-
ponsiveness with a VerifyNow Assay–Impact on Throm-
osis and Safety) trial is randomizing patients who are
eemed nonresponsive to clopidogrel on point-of-care test-
ng to receive higher dosing of clopidogrel (24). Of course,
t might just be a matter of degree—that is, perhaps all
atients benefit from more antiplatelet effect than provided
y standard dosing of clopidogrel, but whether bleeding risk
r cost justify the use of novel agents in all types of patients
emains to be seen. These and other ongoing trials should
elp clarify whether antiplatelet testing is really necessary to
ptimize patient outcomes.
The studies by Saw et al. (9) and Cuisset et al. (10) bring
reat clarity to the field of antiplatelet response. These
eports help reconcile several different studies that have
eached apparently contradictory findings. Different tests of
latelet responsiveness, different study populations, and
ifferent antiplatelet agents might interact in ways that will
ake years to unravel. Relationships between hypercholes-
erolemia and appropriate intensity of cholesterol reduction
herapy continue to be debated despite years of data accu-
ulation, so it should not be surprising that there is much
ore to learn about the appropriate role of measurement of
latelet reactivity. Collectively, these 2 papers illustrate that
he field of antiplatelet resistance is complex and we should
esist the temptation to oversimplify.eprint requests and correspondence: Dr. Deepak L. Bhatt, 75
rancis Street, PB-146, Boston, Massachusetts, 02115. E-mail:
lbhattmd@alum.mit.edu.
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